PRAX - Company ID 0001689548
Praxis Precision Medicines, Inc. trades as PRAX and has a market capitalization of $9.40 B, making it the #998 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$303.00M. This page tracks Praxis Precision Medicines, Inc. through 474 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , Instagram , LinkedIn and Twitter/X .
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Praxis Precision Medicines, Inc.
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - Praxis Precision Medicines, Inc.
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - Praxis Precision Medicines, Inc.
The largest companies sharing Praxis Precision Medicines, Inc.'s SEC industry classification (pharmaceutical preparations).
Praxis Precision Medicines, Inc. (PRAX) has a market capitalization of $9.40 B as of 2026-07-09, ranking #998 among US-listed companies.
Praxis Precision Medicines, Inc. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
In its latest fiscal year Praxis Precision Medicines, Inc. reported a net loss of $303.00M.